Targeted Therapies in Melanoma

被引：8

作者：

Moschos, Stergios J. ^{[1
]}

Pinnamaneni, Ramya ^{[2
]}

机构：

[1] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA

[2] E Carolina Univ, Dept Med, Div Hematol Oncol, Greenville, NC 27834 USA

来源：

SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2015年 / 24卷 / 02期

关键词：

Melanoma; Next generation sequencing; BRAF inhibitors; Ocular melanoma; Immunotherapies; MUTATION-POSITIVE MELANOMA; STAGE-IV MELANOMA; MEK INHIBITION; OPEN-LABEL; BRAF INHIBITION; METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; PROGRESSION-FREE; VEMURAFENIB; SURVIVAL;

D O I：

10.1016/j.soc.2014.12.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advances in the biology of melanoma have provided insights about chemoresistance and its genetic heterogeneity in parallel with advances in drug design, culminating in recent major treatment breakthroughs. Although clinical benefit of targeted therapies has been unquestionable, future advances are only possible if we understand the interplay between genetic aberrations and role of other crucial nongenetic changes yet to be identified by such projects as the Cancer Genome Atlas Project in Melanoma. Combination therapies, either among small molecule inhibitors themselves and/or with immunotherapies, may be the optimal strategy to prevent development of drug resistance inherently linked with such targeted therapies.

引用

页码：347 / +

页数：13

共 59 条

[1] Signatures of mutational processes in human cancer
Alexandrov, Ludmil B.
Nik-Zainal, Serena
Wedge, David C.
Aparicio, Samuel A. J. R.
Behjati, Sam
Biankin, Andrew V.
Bignell, Graham R.
Bolli, Niccolo
Borg, Ake
Borresen-Dale, Anne-Lise
Boyault, Sandrine
Burkhardt, Birgit
Butler, Adam P.
Caldas, Carlos
Davies, Helen R.
Desmedt, Christine
Eils, Roland
Eyfjord, Jorunn Erla
Foekens, John A.
Greaves, Mel
Hosoda, Fumie
Hutter, Barbara
Ilicic, Tomislav
Imbeaud, Sandrine
Imielinsk, Marcin
Jaeger, Natalie
Jones, David T. W.
Jones, David
Knappskog, Stian
Kool, Marcel
Lakhani, Sunil R.
Lopez-Otin, Carlos
Martin, Sancha
Munshi, Nikhil C.
Nakamura, Hiromi
Northcott, Paul A.
Pajic, Marina
Papaemmanuil, Elli
Paradiso, Angelo
Pearson, John V.
Puente, Xose S.
Raine, Keiran
Ramakrishna, Manasa
Richardson, Andrea L.
Richter, Julia
Rosenstiel, Philip
Schlesner, Matthias
Schumacher, Ton N.
Span, Paul N.
Teague, Jon W.
[J]. NATURE, 2013, 500 (7463) : 415 - +
[2] Algazi AP, 2014, ASCO ANN M MAY 30 JU
[3] Angus SP, 2014, AACR ANN M APR 5 9 S
[4] Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
Ascierto, Paolo A.
Simeone, Ester
Sileni, Vanna Chiarion
Pigozzo, Jacopo
Maio, Michele
Altomonte, Maresa
Del Vecchio, Michele
Di Guardo, Lorenza
Marchetti, Paolo
Ridolfi, Ruggero
Cognetti, Francesco
Testori, Alessandro
Bernengo, Maria Grazia
Guida, Michele
Marconcini, Riccardo
Mandala, Mario
Cimminiello, Carolina
Rinaldi, Gaetana
Aglietta, Massimo
Queirolo, Paola
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
[5] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Ascierto, Paolo A.
Schadendorf, Dirk
Berking, Carola
Agarwala, Sanjiv S.
van Herpen, Carla M. L.
Queirolo, Paola
Blank, Christian U.
Hauschild, Axel
Beck, J. Thaddeus
St-Pierre, Annie
Niazi, Faiz
Wandel, Simon
Peters, Malte
Zubel, Angela
Dummer, Reinhard
[J]. LANCET ONCOLOGY, 2013, 14 (03) : 249 - 256
[6] Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Boni, Andrea
Cogdill, Alexandria P.
Dang, Ping
Udayakumar, Durga
Njauw, Ching-Ni Jenny
Sloss, Callum M.
Ferrone, Cristina R.
Flaherty, Keith T.
Lawrence, Donald P.
Fisher, David E.
Tsao, Hensin
Wargo, Jennifer A.
[J]. CANCER RESEARCH, 2010, 70 (13) : 5213 - 5219
[7] Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
Carvajal, Richard D.
Sosman, Jeffrey A.
Quevedo, Jorge Fernando
Milhem, Mohammed M.
Joshua, Anthony M.
Kudchadkar, Ragini R.
Linette, Gerald P.
Gajewski, Thomas F.
Lutzky, Jose
Lawson, David H.
Lao, Christopher D.
Flynn, Patrick J.
Albertini, Mark R.
Sato, Takami
Lewis, Karl
Doyle, Austin
Ancell, Kristin
Panageas, Katherine S.
Bluth, Mark
Hedvat, Cyrus
Erinjeri, Joseph
Ambrosini, Grazia
Marr, Brian
Abramson, David H.
Dickson, Mark Andrew
Wolchok, Jedd D.
Chapman, Paul B.
Schwartz, Gary K.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23): : 2397 - 2405
[8] The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, Ethan
Gao, Jianjiong
Dogrusoz, Ugur
Gross, Benjamin E.
Sumer, Selcuk Onur
Aksoy, Buelent Arman
Jacobsen, Anders
Byrne, Caitlin J.
Heuer, Michael L.
Larsson, Erik
Antipin, Yevgeniy
Reva, Boris
Goldberg, Arthur P.
Sander, Chris
Schultz, Nikolaus
[J]. CANCER DISCOVERY, 2012, 2 (05) : 401 - 404
[9] The Nature and Management of Metastatic Melanoma After Progression on BRAF Inhibitors: Effects of Extended BRAF Inhibition
Chan, Matthew M. K.
Haydu, Lauren E.
Menzies, Alexander M.
Azer, Mary W. F.
Klein, Oliver
Lyle, Megan
Clements, Arthur
Guminski, Alexander
Kefford, Richard F.
Long, Georgina V.
[J]. CANCER, 2014, 120 (20) : 3142 - 3153
[10] BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Colombino, Maria
Capone, Mariaelena
Lissia, Amelia
Cossu, Antonio
Rubino, Corrado
De Giorgi, Vincenzo
Massi, Daniela
Fonsatti, Ester
Staibano, Stefania
Nappi, Oscar
Pagani, Elena
Casula, Milena
Manca, Antonella
Sini, MariaCristina
Franco, Renato
Botti, Gerardo
Caraco, Corrado
Mozzillo, Nicola
Ascierto, Paolo A.
Palmieri, Giuseppe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) : 2522 - 2529

← 1 2 3 4 5 6 →